Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Yeast, wormwood & bacterial genes combine in microbial factory to make antimalarial drug

02.06.2003


By combining genes from three separate organisms into a single bacterial factory, University of California, Berkeley, chemical engineers have developed a simpler, less expensive way to make an antimalaria "miracle" drug that is urgently needed in Third World countries.



The drug, artemisinin, is one of the most promising next-generation antimalarials because of its effectiveness against strains of the malaria parasite now resistant to front-line drugs. It is now too expensive for broad use in countries such as Africa where it is most needed.

"By inserting these genes into bacteria, we’ve given them the ability to make artemisinin quickly, efficiently and cheaply, and in an environmentally friendly way," said Jay D. Keasling, professor of chemical engineering at UC Berkeley. His research is being published online June 1 in Nature Biotechnology and is scheduled to run in the journal’s printed edition in July.


Keasling’s technique for transplanting yeast and plant genes to construct an entirely new metabolic pathway inside bacteria can be used generally to produce a broad family of so-called isoprenoids -- chemical precursors to many plant-derived drugs and chemicals of interest to industry, including the anticancer drug taxol and various food additives. Isoprenoids, found widely in microbes, plants and marine organisms, currently are very expensive for the chemical industry to synthesize from scratch and nearly as expensive to extract from plant material.

"This process could be of interest to everybody -- drug companies making cancer agents, the government producing antibiotics against bioterror agents, or industries making flavors and fragrances," Keasling said. "A company could tweak the bacteria a bit, adding any number of plant genes involved in making the chemical of interest, to get pretty much any isoprenoid. It would be easy to do now."

Keasling’s achievement is a big advance over the day-to-day practice in today’s biotechnology industry. There, protein drugs are produced primarily through fermentation by recombinant yeast that seldom have more than one gene inserted in them, perhaps with an additional piece of DNA fused to that gene to make the yeast spit out the protein.

Scientists have found it much harder to transplant entire gene systems to build new chemical assembly lines. Keasling, however, assembled 10 genes, including control elements, from three different organisms -- bacteria, yeast and wormwood-- and got them to work together successfully.

The goal of Keasling’s group was to create bacteria capable of producing chemicals that can be used to make many kinds of isoprenoids, a class of some 30,000 known compounds of immense interest to the chemical and pharmaceutical industries. Isoprenoids are expensive to synthesize, however, and natural isoprenoids like taxol are costly to isolate from plant material. Often, too, these plants are rare and endangered, so that harvesting causes environmental damage.

Keasling’s approach leapfrogs the bulk of the laborious synthesis necessary today, leaving only a few additional chemical alterations to obtain the desired drug or chemical. The development took more than three years and involved numerous people, primarily Keasling’s UC Berkeley coauthors: post-doctoral fellows Vincent J. J. Martin and Jack D. Newman and graduate students Douglas J. Pitera and Sydnor T. Withers.

Other laboratories have tried to engineer the common intestinal bacteria, E. coli, to make isoprenoid precursors that could be used to produce drugs or industrial chemicals, but the methods involved hijacking the cell’s own production factory. E. coli produce chemicals that can be used to make isoprenoid precursors, but diverting these chemicals to make more of them entails overcoming control mechanisms within the bacterial cell that are not fully understood.

Keasling’s innovation was to leave E. coli’s isoprenoid pathway alone, but transplant a similar pathway from yeast. This pathway takes in a common chemical in E. coli, acetyl co-enzyme A, and sends it down a cascade of reactions resulting in isoprenoid precursors, primarily isopentenyl pyrophospahate (IPP) and dimethylallyl pyrophospate (DMAPP). In initial experiments, these isoprenoids accumulated in the cells and threw then out of whack -- the cells either stopped growing or mutated to avoid the toxins -- so he stuck in a wormwood gene for an enzyme that converts them to amorphadiene, a chemical precursor of artemisinin that the cells can deal with.

Artemisinin has been known to the Chinese for 2,000 years as an herbal medicine, qinghaosu. Though highly effective at killing the malaria parasite, currently it is expensive to manufacture because of the costs of chemical extraction from wormwood (Artemisia annua, a relative of the herb used to make absinthe) or total laboratory synthesis. The expense stands in the way of its use in Africa, where resistance is rapidly spreading to the first-line antimalarial drugs-- chloroquine and sulfadoxine-pyrimethamine.

Since their first success, Keasling and his laboratory colleagues have improved yield from the bacteria 10,000 fold, nearly to the level at which industrial production of the antimalarial drug would be cost effective. Another order of magnitude is doable, he said.

Keasling noted, however, that it is feasible to insert another chemical step into the bacteria to produce a compound, artemisinic acid, that is even closer to artemisinin. And one possibility is to let the bacteria grow and evolve in a petri dish and see if they can produce derivatives of artemisinin that have similar or improved effects on the malaria parasite.

"With the ability to produce taxol or amorphadiene in E. coli, we can easily encourage the bacteria to evolve a molecule not found in nature that could be more effective in human disease," he said.

IPP and DMAPP are precursors to all isoprenoids, which means that the bacterial strains Keasling’s group produced "can serve as platform hosts for the production of any terpenoid compound for which the biosynthetic genes are available," they write in their paper.

The family of isoprenoids includes chemicals called terpenoids, which give plants their aroma and which also include taxol from the Pacific yew tree, and carotenoids, such as the compounds that give plants their color. Aside from their importance in flavorings, colorings and perfumes, isoprenoids from organisms as diverse as coral and fungi are being identified as potential drugs.

"The ability to produce amorphadiene in a simple organism like E. coli opens up a whole realm of possible molecular backbones that can later be functionalized to make drugs," Keasling said.

Keasling’s lab concentrates on metabolic engineering of microbes to do complex chemical syntheses to replace current methods that are expensive, polluting and wasteful of resources.

"Enzymes are very specific catalysts that can accomplish in far fewer steps what takes us many complex steps in the laboratory," Keasling said. "We are trying to put enzymes inside cells to create a biosynthetic cascade using the cell’s metabolites as starting material, to provide essentially complete molecules in an aqueous environment using no toxic reagents. We’re taking an organism, co-opting its metabolism, and using it for our benefit now."

"This is just a start," he emphasized. "I really want to push the limits of the organism."


Keasling’s work was supported by the National Science Foundation, UC BioSTAR and Maxygen, Inc. of Redwood City, Calif.

Robert Sanders | EurekAlert!
Further information:
http://www.berkeley.edu/

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>